Skip to main content

Year: 2021

Shockwave Medical Unveils First One-Year Results of Coronary Intravascular Lithotripsy

New Data at TCT From the Disrupt CAD Clinical Program Demonstrate Consistency of Shockwave IVL Outcomes Over Time, Across Calcium Morphologies and Between Genders SANTA CLARA, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today unveiled new data confirming the safety and effectiveness of coronary IVL out to one year, a new gender analysis that found similar outcomes between men and women, and an OCT analysis that found consistent acute performance in eccentric, concentric and nodular calcified lesions. The data from the Disrupt CAD clinical program were presented in several sessions at the 32nd Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular...

Continue reading

Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 12, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021 and to provide a business overview. To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 6684508. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available...

Continue reading

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10147803. Investors and the public can access the live and archived webcast of this call and a...

Continue reading

Developing Psychedelic Medicine Beyond What We Already Know!

VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will participate in a panel discussion at the Microdose Wonderland: Miami Conference, November 8-9, 2021. This preeminent business gathering in the psychedelic medicine space is bringing together key thought leaders, market influencers, accomplished scientists and researchers, well-known celebrities, leading bankers, entrepreneurs and CEOs. This event will showcase the scientific advancement, clinical progression, and corporate growth of many organizations in the sector. It is expected to draw people from all over the world that are passionate about...

Continue reading

Levitee Labs Announces Gold Sponsorship of Wonderland Psychedelic Conference in Miami

Levitee Labs will be a Gold Sponsor and VIP Lounge Sponsor at the world’s largest psychedelic medicine conference If you would like to attend either of Levitee’s private events, you can register at this link and Levitee Labs’ team will share more details: https://leviteelabs.com/contact/VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) — Levitee Labs Inc. (the “Company” or “Levitee Labs”) (CSE: LVT), (OTC: LVTTF), (FSE: 7H7) an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce its participation as a Gold Sponsor at the Wonderland Miami Conference organized by Microdose. This will be the largest in-person conference in the psychedelic medicine industry. The conference will take place on November 8th and 9th at the Adrienne Arsht Center...

Continue reading

Predictive Analytics Solutions Create New Opportunities for Life Sciences to Address Delayed Diagnosis and other Challenges in Multiple Sclerosis Treatment

OptimizeRx Analysis Details Barriers to Therapy Initiation and Persistence for Multiple Sclerosis Patients ROCHESTER, Mich., Nov. 05, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, published an analysis of multiple sclerosis (MS) research addressing the challenges and common causes of treatment delays and discontinuation in patients with MS, in particular noting the benefits of early MS treatment initiation in slowing disease progression and reducing areas of new damage in the brain and spinal cord. The analysis of existing research helps uncover opportunities for life sciences manufacturers to address the needs of both patients and healthcare providers (HCPs) including leveraging real-world data to inform...

Continue reading

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) — Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference at 4:40 p.m. ET on Tuesday, November 16. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website. About Surrozen Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease...

Continue reading

High Wire Networks Arranges $2.5 Million Financing to Facilitate SVC Closing

Revenue and Income of Secure Voice Corp. Will Service Finance Facility BATAVIA, Ill., Nov. 05, 2021 (GLOBE NEWSWIRE) — High Wire Networks Inc. (the “Company” or “High Wire”) (OTCQB: SGSI), a global provider of technical, professional, electrical and cybersecurity services, announced yesterday that the Company had finalized its agreement to acquire the business of Secure Voice Corp. (SVC), a wholesale network services provider with facilities in the Northeast and carrying traffic across the United States. The acquisition was facilitated through the issuance of a $2.5M secured convertible note to an institutional investor.  The note accrues interest at the rate of 9.9% per annum, and is convertible into the company’s common stock at a fixed conversion price of $0.50 per share. The revenue and income of SVC is expected...

Continue reading

Tree Island Renews Normal Course Issuer Bid

VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) — Tree Island Steel Ltd. (the “Company” or “Tree Island Steel“) (TSX:TSL) announced today that it has received approval from the Toronto Stock Exchange (the “TSX“) to renew its proposed normal course issuer bid to purchase up to 1,421,000 common shares, representing approximately 5% of Tree Island’s issued and outstanding common shares. Purchases under the normal course issuer bid will be made through the facilities of the TSX or any Canadian alternative trading system. The period of the normal course issuer bid will extend from November 9, 2021 to November 8, 2022, or an earlier date should Tree Island Steel complete its purchases. All common shares purchased under the bid will be cancelled. The actual number of common shares...

Continue reading

Mullen Automotive Commences Trading on NASDAQ

Company begins trading under Nasdaq stock ticker symbol “MULN”Mullen Commences Trading on NasdaqMullen trading under Nasdaq ticker symbol “MULN”BREA, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) — via InvestorWire —  Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, is pleased to announce that the Company begins trading today on the Nasdaq Stock Market LLC (“Nasdaq”) under new stock ticker symbol “MULN.”  “Today is a monumental day for Mullen Automotive.  I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq capital markets,” says David Michery, CEO and chairman of Mullen Automotive.  “Trading on Nasdaq now opens us up to new investors, both institutional...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.